EHS
EHS

No increased infection risk after non-intestinal surgery while on biologic

Patients who took Entyvio for the treatment of inflammatory bowel disease did not appear to have an increased risk for developing postoperative infections or other complications following nonintestinal surgery, according to research published in Therapeutic Advances in Gastroenterology.
Paulo Gustavo Kotze, MD, MsC, PhD, of the IBD Outpatient Clinic at Cajuru University Hospital in Curitiba, Brazil, and colleagues wrote that the impact of Entyvio (vedolizumab, Takeda Pharmaceuticals) and other biologic agents on surgical outcomes has long been debated, and various studies on the topic have
EHS
Back to top button